2026-03-09T09:23:46Z https://nagoya.repo.nii.ac.jp/oai

oai:nagoya.repo.nii.ac.jp:02011492 2024-09-05T04:58:58Z 499:508:509:1724896432553

Adenosine triphosphate release inhibitors targeting pannexin1 improve recovery after spinal cord injury Morishita, Kazuaki Nakashima, Hiroaki Machino, Masaaki Ito, Sadayuki Segi, Naoki Miyairi, Yuichi Morita, Yoshinori Imagama, Shiro open access Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International adenosine triphosphate spinal cord injuries receptors purinergic P2X Traumatic spinal cord injury is characterized by immediate and irreversible tissue loss at the lesion site and secondary tissue damage. Secondary injuries should, in principle, be preventable, although no effective treatment options currently exist for patients with acute spinal cord injury. Traumatized tissues release excessive amounts of adenosine triphosphate and activate the P2X purinoceptor 7/pannexin1 complex, which is associated with secondary injury. We investigated the neuroprotective effects of the blue dye Brilliant Blue FCF, a selective inhibitor of P2X purinoceptor 7/pannexin1 that is approved for use as a food coloring, by comparing it with Brilliant Blue G, a P2X7 purinoceptor antagonist, and carbenoxolone, which attenuates P2X purinoceptor 7/pannexin1 function, in a rat spinal cord injury model. Brilliant Blue FCF administered early after spinal cord injury reduced spinal cord anatomical damage and improved motor recovery without apparent toxicity. Brilliant Blue G had the highest effect on this neurological recovery, with Brilliant Blue FCF and carbenoxolone having comparable improvement. Furthermore, Brilliant Blue FCF administration reduced local astrocytic and microglial activation and neutrophil infiltration, and no differences in these histological effects were observed between compounds. Thus, Brilliant Blue FCF protects spinal cord neurons after spinal cord injury and suppresses local inflammatory responses as well as Brilliant Blue G and carbenoxolone. Nagoya University Graduate School of Medicine, School of Medicine 2024-08 eng departmental bulletin paper VoR https://doi.org/10.18999/nagjms.86.3.392 http://hdl.handle.net/2237/0002011492 https://nagoya.repo.nii.ac.jp/records/2011492 10.18999/nagjms.86.3.392 https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/863.html 0027-7622 2186-3326 Nagoya Journal of Medical Science 86 3 392 406 https://nagoya.repo.nii.ac.jp/record/2011492/files/05_Morishita.pdf application/pdf 5.3 MB 2024-08-29